hasIndication
P23161
predicate
Indicates that one entity (typically a product, treatment, or intervention) is intended, approved, or suitable for use in addressing, preventing, or managing a particular condition, purpose, or circumstance.
All labels observed (15)
| Label | Occurrences |
|---|---|
| indication | 265 |
| hasIndication canonical | 169 |
| approvedForIndication | 14 |
| hasIndicationDetail | 6 |
| hasHealthIndication | 5 |
| hasIndicationType | 5 |
| hasPrimaryIndication | 5 |
| indicationType | 5 |
| hasDrugIndication | 3 |
| hasIndicationRegion | 3 |
| hasFDALabelIndication | 2 |
| indicationSubtype | 2 |
| isIndicatedWhen | 2 |
| hasIndicationStatus | 1 |
| leadProductIndication | 1 |
Description generation (PDg)
The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.
Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning. # Instructions Focus on describing the relationship, not the entities themselves. # Response Format Begin the description with \' Indicates...\'
Input
Predicate: hasIndication
Generated description
Indicates that one entity (typically a product, treatment, or intervention) is intended, approved, or suitable for use in addressing, preventing, or managing a particular condition, purpose, or circumstance.
Sample triples (488)
| Subject | Object |
|---|---|
|
Persona knee system
surface form:
Persona Knee System
|
rheumatoid arthritis of the knee via predicate surface "indication" ⓘ |
|
Persona knee system
surface form:
Persona Knee System
|
post-traumatic arthritis of the knee via predicate surface "indication" ⓘ |
|
Persona knee system
surface form:
Persona Knee System
|
failed previous knee replacement via predicate surface "indication" ⓘ |
| Inflectra | rheumatoid arthritis ⓘ |
| Inflectra | Crohn’s disease ⓘ |
| Inflectra | ulcerative colitis ⓘ |
| Inflectra | ankylosing spondylitis ⓘ |
| Inflectra | psoriatic arthritis ⓘ |
| Inflectra | plaque psoriasis ⓘ |
| Ixifi | rheumatoid arthritis ⓘ |
| Ixifi | psoriatic arthritis ⓘ |
| Ixifi | ankylosing spondylitis ⓘ |
| Ixifi | Crohn’s disease ⓘ |
| Ixifi | ulcerative colitis ⓘ |
| Ixifi | plaque psoriasis ⓘ |
| Ixifi | pediatric Crohn’s disease ⓘ |
| Ixifi | pediatric ulcerative colitis ⓘ |
| Avsola | moderate to severe rheumatoid arthritis ⓘ |
| Avsola | active psoriatic arthritis ⓘ |
| Avsola | active ankylosing spondylitis ⓘ |
| Avsola | moderate to severe plaque psoriasis ⓘ |
| Avsola | moderate to severe Crohn's disease ⓘ |
| Avsola | fistulizing Crohn's disease ⓘ |
| Avsola | moderate to severe ulcerative colitis ⓘ |
| andexanet alfa | reversal of anticoagulation due to rivaroxaban ⓘ |
| andexanet alfa | reversal of anticoagulation due to apixaban ⓘ |
| andexanet alfa | treatment of life-threatening bleeding in patients on factor Xa inhibitors ⓘ |
| andexanet alfa | treatment of uncontrolled bleeding in patients on factor Xa inhibitors ⓘ |
| bortezomib | multiple myeloma via predicate surface "indication" ⓘ |
| bortezomib | mantle cell lymphoma via predicate surface "indication" ⓘ |
| bortezomib | relapsed multiple myeloma via predicate surface "indication" ⓘ |
| bortezomib | previously untreated multiple myeloma ineligible for transplant via predicate surface "indication" ⓘ |
| bortezomib | previously untreated mantle cell lymphoma via predicate surface "indication" ⓘ |
| dabigatran | prevention of stroke in nonvalvular atrial fibrillation ⓘ |
| dabigatran | prevention of systemic embolism in nonvalvular atrial fibrillation ⓘ |
| dabigatran | treatment of deep vein thrombosis ⓘ |
| dabigatran | treatment of pulmonary embolism ⓘ |
| dabigatran | reduction in risk of recurrence of deep vein thrombosis ⓘ |
| dabigatran | reduction in risk of recurrence of pulmonary embolism ⓘ |
| dabigatran | venous thromboembolism prophylaxis after hip replacement surgery ⓘ |
| FreeStyle Libre | adults with diabetes via predicate surface "indication" ⓘ |
| FreeStyle Libre | children with diabetes in certain models via predicate surface "indication" ⓘ |
| rimonabant | obesity ⓘ |
| rimonabant | weight management in overweight patients with risk factors ⓘ |
| rimonabant | dyslipidemia ⓘ |
| rimonabant | type 2 diabetes mellitus (adjunct treatment) ⓘ |
| Riabni | non-Hodgkin lymphoma ⓘ |
| Riabni | diffuse large B-cell lymphoma ⓘ |
| Riabni | follicular lymphoma ⓘ |
| Riabni | chronic lymphocytic leukemia ⓘ |